US Patent

US8802637 — Benzylbenzene derivatives and methods of use

Method of Use · Assigned to Theracos Inc · Expires 2028-08-22 · 2y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects benzylbenzene derivatives, including Brenzavvy, for treating diseases and conditions affected by sodium-dependent glucose cotransporter SGLT inhibition.

USPTO Abstract

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

Drugs covered by this patent

Brenzavvy (BEXAGLIFLOZIN) · Theracosbio

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2214`	—	Brenzavvy

Patent Metadata

Patent number: US8802637
Jurisdiction: US
Classification: Method of Use
Expires: 2028-08-22
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Theracos Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.